In December the White House announced a new draft guidance that allows federal agencies to grant nonvoluntary licenses to patents on inventions funded with taxpayer dollars. These are called “march-in ...
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the ...
Drug Licensed from Sanofi Becomes First FDA-Approved Therapy for Ultra-Rare Primary Immunodeficiency
A primary immunodeficiency whose rarity means it can go undiagnosed or misdiagnosed in a patient for years now has its first drug. The FDA has approved a once-daily therapy that addresses the ...
Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The Danish pharma company said it would pay $200 million upfront and up to $1.8 ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. An insurer’s decision to delay reimbursement of drugs licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results